ARROWHEAD RESEARCH (HDP1 MU) stock market data APIs
€24.4421
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
ARROWHEAD RESEARCH Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for HDP1.MU.
Prev. Close
24.4421
Open
24.4421
High
24.4421
Low
24.4421
52 wk Range
8.936-25.15
Market Cap
6 485 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARROWHEAD RESEARCH data using free add-ons & libraries
Get ARROWHEAD RESEARCH Fundamental Data
ARROWHEAD RESEARCH Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARROWHEAD RESEARCH News
New
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
PASADENA, Calif., September 11, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States ...
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
- In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent and long-lasting MAPT mRNA and Tau protein suppression with uniform distribu...
H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy ra...
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits
This article first appeared on GuruFocus. Sep 3 - Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw its shares surge more than 5% on Tuesday after the company announced a licensing deal with Swiss drugmake...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
